Caris Life Sciences, Inc. Common Stock
Here’s whether Caris Life Sciences, Inc. Common Stock (CAI) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+5.27% over 10 days); 3-month momentum positive (+49.8%); rising volume confirms the move (1.37x 30d avg). Concerns: RSI 79 — overbought, elevated pullback risk; weak 1-year return of -41.1%. Currently 48.7% off its 52-week high. Score: +4/7.
CAI is in a confirmed uptrend, trading above both its 50-day ($17.77) and 200-day ($21.12) moving averages. With an RSI of 78.8, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -41.1% compares to +20.4% for SPY (trailed the market by 61.4%). The current 48.7% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.